Skip to main content
BKHA
NASDAQ Life Sciences

Black Hawk Acquisition Corp Secures Up to $300K Convertible Note from Sponsor for DeSPAC Working Capital

Analysis by Wiseek.ai
Sentiment info
Neutral
Importance info
7
Price
$11.6
Mkt Cap
$48.181M
52W Low
$10.09
52W High
$11.95
Market data snapshot near publication time

summarizeSummary

Black Hawk Acquisition Corp. secured a convertible promissory note for up to $300,000 from its sponsor to fund working capital for its ongoing DeSPAC transaction, featuring a highly dilutive conversion price of $1.00 per share.


check_boxKey Events

  • Sponsor Provides Convertible Note

    The company issued a convertible promissory note for up to $300,000 to Black Hawk Management LLC, its sponsor, to cover working capital expenses.

  • Highly Dilutive Conversion Terms

    The note bears 10% interest and is convertible into ordinary shares of the post-merger company at the sponsor's discretion, at a price of $1.00 per share, which is significantly below the current market price of $11.60.

  • Supports DeSPAC Transaction

    This financing is intended to provide necessary capital to facilitate the completion of the company's initial business combination (DeSPAC transaction) with Vesicor Therapeutics, Inc.


auto_awesomeAnalysis

Black Hawk Acquisition Corp. has entered into a convertible promissory note agreement with its sponsor, Black Hawk Management LLC, for up to $300,000. This financing is crucial for providing working capital as the company progresses towards its DeSPAC transaction with Vesicor Therapeutics, Inc., which was previously disclosed in an S-4/A filing on January 23, 2026. While securing capital is vital for the SPAC's operational runway and ability to close the merger, the terms of the note are highly dilutive. The sponsor has the option to convert the principal into ordinary shares of the post-business combination company at a conversion price of $1.00 per share. This conversion price represents a substantial discount compared to the current stock price of $11.60, which is near its 52-week high, indicating significant potential dilution for existing shareholders if the note is converted.

At the time of this filing, BKHA was trading at $11.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.2M. The 52-week trading range was $10.09 to $11.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed BKHA - Latest Insights

BKHA
Apr 20, 2026, 6:23 PM EDT
Filing Type: 10-Q
Importance Score:
9
BKHA
Apr 01, 2026, 5:03 PM EDT
Source: Wiseek News
Importance Score:
8
BKHA
Apr 01, 2026, 4:56 PM EDT
Filing Type: 8-K
Importance Score:
9
BKHA
Mar 17, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
8
BKHA
Mar 06, 2026, 5:15 PM EST
Source: Wiseek News
Importance Score:
9
BKHA
Mar 06, 2026, 5:12 PM EST
Filing Type: 10-K
Importance Score:
9
BKHA
Mar 04, 2026, 8:21 PM EST
Filing Type: S-4/A
Importance Score:
9
BKHA
Feb 19, 2026, 3:13 PM EST
Filing Type: 8-K
Importance Score:
7
BKHA
Feb 03, 2026, 1:07 PM EST
Filing Type: 8-K
Importance Score:
7
BKHA
Jan 22, 2026, 9:44 PM EST
Filing Type: S-4/A
Importance Score:
9